Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Arcellx Inc
ACLXCurrent price
86.17 USD
+0.83 USD (+0.97%)
Last closed
84.27 USD
Company
arcellx.com
ISIN
US03940C1009
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
4 740 708 864 USD
Yield for 12 month
+93.08 %
1Y
3Y
5Y
10Y
15Y
ACLX
Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company's preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, it focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California. Address: 800 Bridge Parkway, Redwood City, CA, United States, 94065
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
93.38 USDP/E ratio
–Dividend Yield
–Current Year
+110 319 000 USD
Last Year
+17 912 000 USD
Current Quarter
+27 384 000 USD
Last Quarter
+39 256 000 USD
Current Year
+108 279 000 USD
Last Year
-2 224 000 USD
Current Quarter
+26 145 000 USD
Last Quarter
+38 430 000 USD
Key Figures ACLX
1 year
3 years
5 years
10 years
EBITDA
-77 432 000 USD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-7.43 %
PEG Ratio
–
Return On Equity TTM
-13.8 %
Wall Street Target Price
93.38 USD
Revenue TTM
144 746 000 USD
Book Value
9.08 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
91.5 %
Dividend Yield
–
Gross Profit TTM
–
Earnings per share
-1.04 USD
Diluted Eps TTM
-1.04 USD
Most Recent Quarter
II 2024
Quarterly Earnings Growth YOY
–
Profit Margin
-37.23 %
Dividend Analytics ACLX
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History ACLX
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
–
Payout Ratio
–
Last Split Date
–
Dividend Date
–
Stock Valuation ACLX
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
28.2546
Price Sales TTM
32.7519
Enterprise Value EBITDA
-6.5219
Price Book MRQ
9.3031
Financials ACLX
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators ACLX
For 52 weeks
32.9 USD
97.54 USD
50 Day MA
78.65 USD
Shares Short Prior Month
3 961 071
200 Day MA
63.98 USD
Short Ratio
7.94
Shares Short
4 167 217
Short Percent
8.88 %
BeatStart